CH311611A - Process for the production of a new basic substituted fatty acid (2-halogen-6-methyl-anilide). - Google Patents

Process for the production of a new basic substituted fatty acid (2-halogen-6-methyl-anilide).

Info

Publication number
CH311611A
CH311611A CH311611DA CH311611A CH 311611 A CH311611 A CH 311611A CH 311611D A CH311611D A CH 311611DA CH 311611 A CH311611 A CH 311611A
Authority
CH
Switzerland
Prior art keywords
anilide
methyl
fatty acid
halogen
substituted fatty
Prior art date
Application number
Other languages
German (de)
Inventor
Aktiengesellschaft Cilag
Original Assignee
Cilag Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cilag Ag filed Critical Cilag Ag
Publication of CH311611A publication Critical patent/CH311611A/en

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

  

  Verfahren zur     Herstellung    eines neuen basisch     substituierten    Fettsäure.       (2-halogen.6-methyl-anilids).       Gegenstand     des    vorliegenden Patentes bil  det ein Verfahren zur Herstellung eines neuen       basisch    substituierten     Fettsäure-(2-halogen-6-          methyl-anilids),        welches    dadurch gekennzeich  net ist,     d'ass    man eine Verbindung der Formel  
EMI0001.0010     
    in welcher X einen reaktionsfähigen, während  der Reaktion sich abspaltenden Rest bedeutet,  mit.     n-Butylamin        umsetzt..     



  Der Rest X     kann.    in einem     Halogenatom     oder einem sonstigen für den Austausch gegen  den     basischen    Rest geeigneten reaktionsfähi  gen     Substituenten,    wie z. B. einer     A.lkylsul-          tonploxy-    oder     Arylsulfonyloxygruppe,    beste  hen. Der Austausch der Gruppe X gegen den       n-Butylaminrest    erfolgt, z.

   B. durch einfaches  Erwärmen mit     n-Butylamin    gegebenenfalls in       Gegenwart    eines basisch reagierenden Konden  sationsmittels oder von     n-Butylamin    im L     ber-          schuss.    Das     n-Butylamino-aeet-(2-chlor-6-me-          thy1-a.nilid)    ist. ein farbloses, unter 0,02 mm     Hg     bei     140-143     siedendes öl. Das     Hydroehlorid     der Base schmilzt bei 231-233 .  



  Das neue     Anilid    soll als Lokalanästhetikum  und als Zwischenprodukt zur Herstellung wei  terer Derivate     Verwendung    finden.    <I>Beispiel:</I>  50 Gewichtsteile     Chloracet-(2-chlor-6-me-          thyl-anilid)    (gewonnen     dureh    Umsetzen von     2-          (,'hlor-6-methyl-anilin    mit     Chloracetylchlorid     in Gegenwart von     Na.triumacetat,        Schmp.    140  bis 141 )

   werden in 100     Gewiehtsteilen    Ben  zol     suspendiert    und mit 150     Gewichtsteilen          n-Butylamin    versetzt. Die Temperatur steigt  dabei leicht an und ein grosser Teil des Reak  tionsgemisches geht. in Lösung. Nun wird  während 4 Stunden bei Zimmertemperatur ge  rührt und dann einige Stunden bei 60-65 .  Das überschüssige     Butylamin    wird     abdestil-          liert,    der Rückstand mit Natronlauge versetzt       und    das sich abscheidende<B>öl</B> in Äther aufge  nommen.

   Nach dem Trocknen der ätherischen  Lösung und Verjagen des     Lösungsmittels    ver  bleibt ein öl, das durch Vakuumdestillation  gereinigt. wird.     Ma.n    erhält. 55 Gewichtsteile  reines     n-But.,ylaminoacet-(2-chlor-6-metltyl-          anilid),    was einer Ausbeute von 93 /o- ent  spricht.



  Process for the production of a new basic substituted fatty acid. (2-halogen.6-methyl-anilide). The subject of the present patent bil det a process for the preparation of a new basic substituted fatty acid (2-halo-6-methyl-anilide), which is characterized by having a compound of the formula
EMI0001.0010
    in which X denotes a reactive radical which is split off during the reaction, with. n-butylamine converts.



  The rest of X can. in a halogen atom or other reactive substituents suitable for replacement with the basic radical, such as. B. an A.lkylsul- tonploxy or arylsulfonyloxy group, best hen. The group X is exchanged for the n-butylamine residue, e.g.

   B. by simply heating with n-butylamine, optionally in the presence of a basic condensation agent or n-butylamine in excess. The n-butylamino-aeet- (2-chloro-6-methy1-a.nilid) is. a colorless oil boiling below 0.02 mm Hg at 140-143. The hydrochloride of the base melts at 231-233.



  The new anilide is to be used as a local anesthetic and as an intermediate for the production of further derivatives. <I> Example: </I> 50 parts by weight of chloroacet- (2-chloro-6-methyl-anilide) (obtained by reacting 2- (, 'chloro-6-methyl-aniline with chloroacetyl chloride in the presence of Na. trium acetate, melting point 140 to 141)

   are suspended in 100 parts by weight of benzene and mixed with 150 parts by weight of n-butylamine. The temperature rises slightly and a large part of the reaction mixture goes. in solution. The mixture is then stirred for 4 hours at room temperature and then for a few hours at 60-65. The excess butylamine is distilled off, sodium hydroxide solution is added to the residue and the <B> oil </B> which separates out is taken up in ether.

   After the essential solution has dried and the solvent has been driven off, an oil remains which is purified by vacuum distillation. becomes. You get. 55 parts by weight of pure n-but., Ylaminoacet- (2-chloro-6-methyl-anilide), which corresponds to a yield of 93%.

 

Claims (1)

PATENTANSPRUCIl Verfahren zur Herstellung eines neuen basisch substituierten Fettsäure-(2-halogen-6- methyl-anilids), dadurch gekennzeichnet., dass man eine Verbindung der Formel EMI0001.0056 in welcher X einen reaktionsfähigen, während der Reaktion sich abspaltenden Rest bedeutet, mit. n-Butylamin umsetzt. Das auf diese Weise erhaltene n-Butylamino-acet-(2-chlor-6-inet.hyl- anilid) bildet ein farbloses, unter 0,02 mm Hg bei 140-143 siedendes Öl. Das Hydrochlorid der Base schmilzt bei 231-233 . PATENT CLAIM A process for the preparation of a new basic substituted fatty acid (2-halogen-6-methyl-anilide), characterized in that a compound of the formula EMI0001.0056 in which X denotes a reactive radical which is split off during the reaction, with. n-butylamine converts. The n-butylamino-acet- (2-chloro-6-inet.hyl anilide) obtained in this way forms a colorless oil which boils below 0.02 mm Hg at 140-143. The hydrochloride of the base melts at 231-233. Das neue Unilid soll als Lolialanästlietikuiii und als Zwischenprodukt Verwendung finden. UNTERANSPRUCH: Verfahren nach Patenta.nsprueh, dadurch gekennzeichnet, dass man ein Halbgenacet-(2- chlor-6-methyl-anilid) mit n-Butylamin reagie ren lässt. The new Unilid should be used as a Lolialanästlietikuiii and as an intermediate product. SUBSTANTIAL CLAIM: Process according to Patenta.nsprueh, characterized in that a half-gen acetone (2-chloro-6-methyl-anilide) is allowed to react with n-butylamine.
CH311611D 1952-02-25 1952-02-25 Process for the production of a new basic substituted fatty acid (2-halogen-6-methyl-anilide). CH311611A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH311611T 1952-02-25
CH307799T 1952-11-25

Publications (1)

Publication Number Publication Date
CH311611A true CH311611A (en) 1955-11-30

Family

ID=25735344

Family Applications (1)

Application Number Title Priority Date Filing Date
CH311611D CH311611A (en) 1952-02-25 1952-02-25 Process for the production of a new basic substituted fatty acid (2-halogen-6-methyl-anilide).

Country Status (1)

Country Link
CH (1) CH311611A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10786485B1 (en) 2019-03-11 2020-09-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10842798B1 (en) 2019-11-06 2020-11-24 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10927096B2 (en) 2019-03-11 2021-02-23 Nocion Therapeutics, Inc. Ester substituted ion channel blockers and methods for use
US10933055B1 (en) 2019-11-06 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10934263B2 (en) 2019-03-11 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10968179B2 (en) 2019-03-11 2021-04-06 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US11332446B2 (en) 2020-03-11 2022-05-17 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11377422B2 (en) 2019-03-11 2022-07-05 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10934263B2 (en) 2019-03-11 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10828287B2 (en) 2019-03-11 2020-11-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US11643404B2 (en) 2019-03-11 2023-05-09 Nocion Therapeutics, Inc. Ester substituted ion channel blockers and methods for use
US10927096B2 (en) 2019-03-11 2021-02-23 Nocion Therapeutics, Inc. Ester substituted ion channel blockers and methods for use
US11603355B2 (en) 2019-03-11 2023-03-14 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10786485B1 (en) 2019-03-11 2020-09-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10968179B2 (en) 2019-03-11 2021-04-06 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US11512058B2 (en) 2019-03-11 2022-11-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10933055B1 (en) 2019-11-06 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10842798B1 (en) 2019-11-06 2020-11-24 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US11696912B2 (en) 2019-11-06 2023-07-11 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US11332446B2 (en) 2020-03-11 2022-05-17 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use

Similar Documents

Publication Publication Date Title
CH311611A (en) Process for the production of a new basic substituted fatty acid (2-halogen-6-methyl-anilide).
CH311607A (en) Process for the production of a new basic substituted fatty acid (2-halogen-6-methyl-anilide).
CH311606A (en) Process for the production of a new basic substituted fatty acid (2-halogen-6-methyl-anilide).
CH311615A (en) Process for the production of a new basic substituted fatty acid (2-halogen-6-methyl-anilide).
CH311609A (en) Process for the production of a new basic substituted fatty acid (2-halogen-6-methyl-anilide).
CH311613A (en) Process for the production of a new basic substituted fatty acid (2-halogen-6-methyl-anilide).
CH311614A (en) Process for the production of a new basic substituted fatty acid (2-halogen-6-methyl-anilide).
CH311610A (en) Process for the production of a new basic substituted fatty acid (2-halogen-6-methyl-anilide).
CH311608A (en) Process for the production of a new basic substituted fatty acid (2-halogen-6-methyl-anilide).
CH311612A (en) Process for the production of a new basic substituted fatty acid (2-halogen-6-methyl-anilide).
CH311616A (en) Process for the production of a new basic substituted fatty acid (2-halogen-6-methyl-anilide).
CH311617A (en) Process for the production of a new basic substituted fatty acid (2-halogen-6-methyl-anilide).
CH311619A (en) Process for the production of a new basic substituted fatty acid (2-halogen-6-methyl-anilide).
DE1108213B (en) Process for the preparation of 2,2-dimethyl-3-phenylcyclopropane-carboxylic acids
CH311620A (en) Process for the production of a new basic substituted fatty acid (2-halogen-6-methyl-anilide).
CH311603A (en) Process for the production of a new basic substituted fatty acid (2-halogen-6-methyl-anilide).
CH311604A (en) Process for the production of a new basic substituted fatty acid (2-halogen-6-methyl-anilide).
CH328671A (en) Process for the production of a new basic substituted fatty acid-2-halogen-6-methyl-anilide
CH311628A (en) Process for the production of a new basic substituted fatty acid (2-halogen-6-methyl-anilide).
AT222650B (en) Process for the production of new ethers
CH311626A (en) Process for the production of a new basic substituted fatty acid (2-halogen-6-methyl-anilide).
CH311637A (en) Process for the production of a new basic substituted fatty acid (2-halogen-6-methyl-anilide).
CH311622A (en) Process for the production of a new basic substituted fatty acid (2-halogen-6-methyl-anilide).
CH311618A (en) Process for the production of a new basic substituted fatty acid (2-halogen-6-methyl-anilide).
CH311605A (en) Process for the production of a new basic substituted fatty acid (2-halogen-6-methyl-anilide).